	US 12,102,628 B2
	Composition and methods for the treatment of myopia
Hui Ouyang, Irvine, CA (US); and Yong Qiu, San Diego, CA (US)
Assigned to Seinda Pharmaceutical Guangzhou Corporation
Filed by Seinda Pharmaceutical Guangzhou Corporation, Guangdong (CN)
Filed on Mar. 28, 2022, as Appl. No. 17/706,225.
Application 17/706,225 is a continuation of application No. 16/632,105, granted, now 11,285,141, previously published as PCT/US2018/043059, filed on Jul. 20, 2018.
Claims priority of provisional application 62/535,111, filed on Jul. 20, 2017.
Prior Publication US 2023/0062844 A1, Mar. 2, 2023
Int. Cl. A61P 27/02 (2006.01); A61K 9/00 (2006.01); A61K 31/06 (2006.01); A61K 31/216 (2006.01); A61K 31/222 (2006.01); A61K 31/24 (2006.01); A61K 31/4168 (2006.01); A61K 31/417 (2006.01); A61K 31/439 (2006.01); A61K 31/4406 (2006.01); A61K 31/46 (2006.01); A61K 31/498 (2006.01); A61K 31/551 (2006.01); A61K 31/5513 (2006.01); A61P 27/10 (2006.01); C07C 217/20 (2006.01); C07C 219/10 (2006.01); C07D 213/04 (2006.01); C07D 235/02 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 471/08 (2006.01); C07D 487/04 (2006.01); C07D 491/18 (2006.01)

CPC A61K 31/46 (2013.01) [A61K 9/0048 (2013.01); A61K 31/24 (2013.01); A61K 31/4168 (2013.01); A61K 31/417 (2013.01); A61K 31/498 (2013.01); A61K 31/551 (2013.01); A61P 27/10 (2018.01)]

15 Claims

1. A method of inhibiting, slowing, or preventing progression of myopia in the eye, the method comprising administering to an eye of a subject, during a treatment period, a composition comprising:

a non-selective muscarinic receptor antagonist comprising one or more of cyclopentolate, homatropine, hyoscine, amidoamine, or a pharmaceutically acceptable salt thereof; and

a miotic agent comprising one or more of brimonidine, bunazosin, thymoxamine, apraclonidine, and phentolamine, or a pharmaceutically acceptable salt thereof.